Business
GenSight Biologics Reaches Agreement with ANSM for Opening of LUMEVOQ® Named Early Access Program (AAC) in France
PARIS, June 12, 2025--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/0fc11b96a2cbdd069141018c3bb71c5b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/jDPW6VnRtz6ocxb9FfzW0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0fc11b96a2cbdd069141018c3bb71c5b","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Agreement to consider opening the French Early Access Program expeditiously after approval of a dose-ranging study","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Design for dose-ranging study submitted, with clinical trial application targeted for Q3 2025","length":93,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Opening of AAC targeted for Q4 2025 at the latest","length":49,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Multiple near-term value catalysts expected over next 12 months","length":63,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":319,"olType":false},{"type":"text","content":"PARIS, June 12, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that it has reached agreement with the French medicines safety agency ANSM to consider expeditiously opening the French named early access program (AAC) for LUMEVOQ® upon approval of a dose-ranging clinical study.","length":530,"tagName":"p"},{"type":"text","content":"Clear Path Forward for LUMEVOQ® AAC Program in France","length":53,"tagName":"p"},{"type":"text","content":"Following extensive discussions, GenSight reached alignment with ANSM on a plan to open the LUMEVOQ® AAC program. The agency has agreed that the authorization of a focused dose-ranging study could enable the opening of the early access program. The Company has submitted a preliminary design of the study to the agency and aims to finalize...